An exciting new CAR T-cell product, which targets SLAMF7 (CS1, CD319), is displaying exciting preliminary results against multiple myeloma (MM) cells. In this interview, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses its underlying design and mechanism of action, as well as the results of tests performed so far in vitro, in vivo and on patient-derived MM cells. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
New CAR T-cell targeting SLAMF7 shows efficacy against multiple myeloma
